Hepatology communications · 2025
3D-bioprinted liver cancer models derived from primary hepatocytes for simulating cancer initiation and drug screening.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Yuanyuan, Li Yuxin, Zhang Wenjie, Jiang Hongyan, Mao Lina, He Runbang, Ma Yue, Wang Qiangsong, Huang Pengyu
Аннотация
BACKGROUND: HCC remains one of the most lethal cancers globally, and accurately replicating the early events of tumor evolution remains a critical challenge.
METHODS: In this study, we developed early-stage liver cancer cell lines by introducing distinct combinations of oncogenes into primary mouse hepatocytes. Using 3D bioprinting technology, combined with bioinks composed of gelatin and alginate, we constructed a more precise representation of liver cancer tissue to better simulate key tumor characteristics.
RESULTS: Our·findings revealed that different oncogene combinations produced unique drug response profiles, with Ras-driven cells exhibiting heightened sensitivity to ferroptosis. Furthermore, 3D bioprinting tumor tissues derived from transformed hepatocytes effectively captured early HCC characteristics. These models preserved key features of early-stage liver cancer and provided a reliable platform for drug screening. Importantly, the 3D models demonstrated higher resistance to chemotherapy and targeted therapies compared with 2D cultures.
CONCLUSIONS: In summary, we established both 2D and 3D models that replicate early HCC progression, offering valuable tools for drug screening and advancing our understanding of early carcinogenic mechanisms.
METHODS: In this study, we developed early-stage liver cancer cell lines by introducing distinct combinations of oncogenes into primary mouse hepatocytes. Using 3D bioprinting technology, combined with bioinks composed of gelatin and alginate, we constructed a more precise representation of liver cancer tissue to better simulate key tumor characteristics.
RESULTS: Our·findings revealed that different oncogene combinations produced unique drug response profiles, with Ras-driven cells exhibiting heightened sensitivity to ferroptosis. Furthermore, 3D bioprinting tumor tissues derived from transformed hepatocytes effectively captured early HCC characteristics. These models preserved key features of early-stage liver cancer and provided a reliable platform for drug screening. Importantly, the 3D models demonstrated higher resistance to chemotherapy and targeted therapies compared with 2D cultures.
CONCLUSIONS: In summary, we established both 2D and 3D models that replicate early HCC progression, offering valuable tools for drug screening and advancing our understanding of early carcinogenic mechanisms.